ATNM on NYSE
Actinium Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Citius Pharmaceuticals, Inc., Incannex Healthcare Inc. or Zynerba Pharmaceuticals, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$21.1M
Out of $90.0K in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Total revenue | $90.0K | |
| Research and development, net of reimbursements | $21.1M | $30.0M |
| General and administrative | $15.2M | $12.1M |
| Total operating expenses | $36.3M | $42.1M |
| Loss from operations | -$36.2M | -$42.1M |
| Interest income net | $2.4M | $3.9M |
| Total other income | $2.4M | $3.9M |
| Net loss | -$33.9M | -$38.2M |
| Net loss per common share basic (in Dollars per share) | -$1.09 | -$1.27 |
| Net loss per common share diluted (in Dollars per share) | -$1.09 | -$1.27 |
| Weighted average common shares outstanding basic (in Shares) | 31.2M shares | 30.1M shares |
| Weighted average common shares outstanding diluted (in Shares) | 31.2M shares | 30.1M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $48.0M | $72.9M | |
| Prepaid expenses and other current assets | $1.4M | $1.6M | |
| Total Current Assets | $49.4M | $74.5M | |
| Property and equipment, net of accumulated depreciation of $1,064 and $891 | $295.0K | $364.0K | |
| Restricted cash long term | $335.0K | $324.0K | |
| Operating lease right-of-use assets | $1.8M | $1.7M | |
| Finance leases right-of-use assets | $10.0K | $20.0K | |
| Total Assets | $51.8M | $76.9M | |
| Accounts payable and accrued expenses | $7.2M | $7.6M | |
| Operating leases current liability | $711.0K | $569.0K | |
| Finance leases current liability | $11.0K | $11.0K | |
| Total Current Liabilities | $8.0M | $8.1M | |
| Long-term license revenue deferred | $35.0M | $35.0M | |
| Long-term operating lease obligations | $972.0K | $984.0K | |
| Long-term finance lease obligations | $9.0K | ||
| Total Liabilities | $43.9M | $44.1M | |
| Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 shares issued and outstanding at December 31, 2025 and 2024, respectively | $31.0K | $31.0K | |
| Additional paid-in capital | $417.5M | $408.6M | |
| Accumulated other comprehensive loss | -$20.0K | ||
| Accumulated deficit | -$409.7M | -$375.8M | |
| Total Stockholders Equity | $7.8M | $32.8M | $36.4M |
| Total Liabilities and Stockholders Equity | $51.8M | $76.9M | |
| Property and equipment, net of accumulated depreciation | $1.1M | $891.0K | |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in Shares) | 50.0M shares | 50.0M shares | |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 1.0B shares | 1.0B shares | |
| Common stock, shares issued (in Shares) | 31.2M shares | 31.2M shares | |
| Common stock, shares outstanding (in Shares) | 31.2M shares | 31.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$33.9M | -$38.2M |
| Stock-based compensation expense | $9.2M | $5.3M |
| Depreciation expense | $173.0K | $197.0K |
| Amortization of right-of-use assets | $648.0K | $614.0K |
| Prepaid expenses and other current assets | $219.0K | -$15.0K |
| Accounts payable and accrued expenses | -$346.0K | -$387.0K |
| Operating lease liabilities | -$577.0K | -$530.0K |
| Net Cash Used In Operating Activities | -$24.6M | -$33.1M |
| Purchase of property and equipment | -$104.0K | -$11.0K |
| Net Cash Used In Investing Activities | -$104.0K | -$11.0K |
| Payments on finance leases | -$10.0K | -$9.0K |
| Proceeds from sales of shares of common stock, net of offering costs | $29.3M | |
| Restricted stock units withheld to cover tax obligations | -$207.0K | |
| Proceeds from the exercise of stock options | $75.0K | |
| Net Cash (Used In) Provided By Financing Activities | -$217.0K | $29.3M |
| Effect of foreign currency rates on cash | $6.0K | |
| Net Change in Cash, Cash Equivalents and Restricted Cash | -$24.9M | -$3.8M |
| Right-of-use assets obtained in exchange for lease liabilities | $708.0K |
Former names
- Cactus Ventures, Inc.Feb 5, 2007 to Mar 29, 20132
Recent filings
- Oct 9, 2026S-8 REGISTRATION STATEMENT
- Sep 10, 20263
- Sep 10, 20263
- Sep 4, 20264
- Sep 4, 20264
- Sep 4, 20264
- Sep 4, 20264
- Sep 4, 20264
- Sep 4, 20264
- Aug 14, 20268-K CURRENT REPORT
- Aug 7, 202610-Q QUARTERLY REPORT
- Jun 18, 20268-K CURRENT REPORT
- May 29, 20268-K CURRENT REPORT
- May 8, 202610-Q QUARTERLY REPORT
- Mar 30, 202610-K ANNUAL REPORT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10